Healing through innovation, competence and partnership

GBG Forschungs GmbH is a professional institute dedicated to breast cancer research. It was founded in 2003 by Prof. Dr. med. Gunter von Minckwitz, and led by Prof. Dr. med. Sibylle Loibl (CEO). The institute serves Germany’s largest breast cancer study group, the German Breast Group, as a platform for implementing academically orientated clinical trials.

The German Breast Group, a cooperative academic study group, and GBG Forschungs GmbH, a professional research institute, conduct high-quality clinical breast cancer trials on a joint basis. Our work is always guided by our philosophy: “Healing through innovation, competence and partnership”.

Effective treatment is the key to cure. Our clinical studies on the efficacy of breast cancer treatments supplement research carried out by manufacturers of pharmaceuticals and medicinal products, thus ensuring a well-balanced understanding of the disease. Our work is based on the principles of high quality standards, scientific independence and professional neutrality – in the interests of achieving the best possible results.

Together with a large number of recognised breast cancer experts, the members of the German Breast Group’s sub-boards develop innovative ideas for new academically orientated trial concepts. Our studies cover very different stages and types of breast cancer. In addition, the clinical investigators research new methods of prevention for women with an increased risk of breast cancer.

Thanks to the fact that GBG Forschungs GmbH is highly specialised in breast cancer, our trial designs and results comply with the stringent statutory requirements for scientific studies. In the interests of safeguarding these quality standards on a permanent basis, our corporate structure is multifaceted and optimally geared towards trial processes.

Our research is underpinned by collaboration and partnership: we conduct successful clinical trials in cooperation with a network of 500 study centres and over 1,000 clinical investigators. In order to reflect medical progress in our investigations, we maintain close links with national and international study groups as well as leading pharmaceutical manufacturers. Together we are able to combine the latest drugs in a targeted way and provide optimal therapy recommendations.